AKAkshay Kohli

Akshay Kohli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akshay Kohli has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Connectomics in aging and cognition

    by Barbara B. Bendlin, Akshay Kohli, Shi-Jiang Li

  • Open Access

    Assessment of myelin in Alzheimer’s by a R1 and the relationship to amyloid burden

    by Alfredo D Bolaños, Akshay Kohli, Steven R Kecskemeti, Andrew L Alexander, Tobey J Betthauser, Mary‐Elizabeth Pasquesi, Veena A. Nair, Vivek Prabhakaran, Shi‐Jiang Li, Barbara B Bendlin

    Background: Alzheimer’s disease (AD) is well known as a grey matter disorder, characterized by substantial and progressive neurodegeneration. However, less is known about myelin loss in AD, particularly as the disease progresses in severity. To gain a better insight on the role of myelin over the clinical and biologic progression of AD, we tested for differences in quantitative relaxometry R1, a metric sensitive to brain myelin, among individuals who were cognitively unimpaired (CU), diagnosed with mild cognitive impairment (MCI), and diagnosed with AD, in addition to testing for associations between R1 and amyloid PET. Understanding the course of myelin injury in disease progression is expected to address the gap in knowledge about the trajectory of myelin alterations in AD.Methods: Participants from the Alzheimer’s Disease Connectome Project underwent T1‐weighted (T1w) MPnRAGE with motion‐correction and amyloid imaging with [11C]PiB PET. Composite T1w images and R1 maps were reconstructed at 1mm isotropic resolution. T1w scans were bias‐field corrected and denoised before undergoing tissue segmentation. R1 was sampled and bilaterally averaged across cortical‐adjacent white matter (WM). An average WM‐R1 was generated for each participant by calculating the mean of cortical regions R1. MANOVA and regression analyses were used to analyze the difference and relationship between each group’s WM‐R1 and PiB‐Index.Result: The three groups showed an association with PiB‐Index and WM‐R1, Pillai’s Trace = 0.28, F(4, 110) = 4.56, p2 = 0.64, F(1, 6) = 10.99, p = 0.016.Conclusion: Our findings indicate myelin differences by clinical status, in addition to relationships between amyloid and R1 indices of myelin. While AD was associated with lower myelin as indexed by R1, we unexpectedly found that higher cortical amyloid in AD was associated with higher myelin indexed by R1, suggesting an increase in myelination as AD progresses. Overall, lower myelin in clinical AD, accompanied by the higher myelin with greater amyloid burden suggests possible reparative mechanisms in response to neurodegeneration in AD.

  • The relationship of glucose-stimulated insulin secretion to cerebral glucose metabolism and cognition in healthy middle-aged and older adults

    by Gilda E. Ennis, Akshay Kohli, Erin M. Jonaitis, Tobey J. Betthauser, Jennifer M. Oh, Chase E. Taylor, Nathaniel Chin, Rebecca L. Koscik, Bradley T. Christian, Sanjay Asthana, et al.


  • Open Access

    IMPROVING RATE OF LUNG CANCER SCREENING IN PRIMARY CARE CLINIC

    by Akshay Kohli, Anika Bhargava, Irina Veytsman


  • Open Access

    P057 IMPROVED QUALITY OF CARE AND QUALITY OF LIFE FOR IBD PATIENTS USING MOBILE BASED REMOTE MONITORING PLATFORM: A RANDOMIZED CONTROL TRIAL

    by Ashish Atreja, Emamuzo Otobo, Eva Szigethy, Akshay Kohli, Hersh Shroff, Helena Chang, Jason Rogers, Thomas Ullman, Benjamin Cohen, Steven Itzkowitz, et al.

    The recurrent and debilitating nature of Inflammatory Bowel Disease (IBD) makes affected patients ideal candidates to assess the therapeutic potential of a digital intervention for long-term patient management. HealthPROMISE is an innovative software platform designed to improve health outcomes by increasing patient engagement, self-management skills and communication transparency. The study aims to understand the impact of the use of a mobile based remote app on improving quality of care (QOC), health outcomes and quality of life (QOL) in IBD patients. Demographic information and baseline e-PROs (Patient-Reported Outcomes) were measured using online questionnaires delivered through the mobile based monitoring app. In the app, patients update their information and receive a disease summary of QOC metrics and IBD-specific QOL trends. Patient data was monitored in real-time and communicated with the care team and patients as needed. •320 patients were enrolled and randomized to intervention (162) and control (158) group (Fig.1) •IBD-QOL significantly improved among HealthPROMISE patients over a follow-up of 575 days (25.2 ± 11.3 vs. 30.3 ± 11.3 baseline, p<0.001). •Uncontrolled anxiety and fatigue were major drivers of poor QOL. •Patients with a college education reported significantly less symptom burden (29.3vs 36.8, range 10–70; P<0.001). •After a follow-up of 575 ± 135 days, more significant increase in QOC was observed among HealthPROMISE users (+34 ppt vs. +15 ppt, p<0.01) (Fig.2). A significant improvement in QOC was observed among patients using the mobile based app, who also reported more equitable participation in their care decision-making process and improved health outcomes. Digital health interventions and IBD remote monitoring can address gaps in QOC, increase patient engagement, improve QOL and health outcomes. This is one of the first randomized controlled trials of app-based PRO in IBD patients. Study inclusion/exclusion criteria flowchart. Study inclusion/exclusion criteria flowchart. Change in percentage of patients meeting eligible qoc metrics at 495 days from baseline (+9 pp control vs. +28 Pp healthpromise, p<0.01) And at 575 days from baseline (+15 ppt control vs. +34 Ppt healthpromise, p<0.01). Change in percentage of patients meeting eligible qoc metrics at 495 days from baseline (+9 pp control vs. +28 Pp healthpromise, p<0.01) And at 575 days from baseline (+15 ppt control vs. +34 Ppt healthpromise, p<0.01).